Drug exposure and psoriasis vulgaris: Case-control and case-crossover studies

被引:57
作者
Cohen, AD
Bonneh, DY
Reuveni, H
Vardy, DA
Naggan, L
Halevy, S
机构
[1] Soroka Univ, Dept Dermatol, Med Ctr, Beer Sheva, Israel
[2] Ben Gurion Univ Negev, Clalit Hlth Serv, IL-84105 Beer Sheva, Israel
[3] Ben Gurion Univ Negev, Siaal Res Ctr Family Med & Primary Care, IL-84105 Beer Sheva, Israel
[4] Ben Gurion Univ Negev, Epidemiol & Hlth Serv Evaluat Dept, IL-84105 Beer Sheva, Israel
[5] Ben Gurion Univ Negev, Fac Hlth Sci, IL-84105 Beer Sheva, Israel
关键词
psoriasis vulgaris; drug reactions; angiotensin-converting enzyme inhibitors; beta-blockers; non-steroidal anti-inflammatory drugs;
D O I
10.1080/00015550510032823
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Intake of drugs is considered a risk factor for psoriasis. The aim of this study was to investigate the association between drugs and psoriasis. A case-control study including 110 patients who were hospitalized for extensive psoriasis was performed. A control group (n=515) was defined as patients who had undergone elective surgery. A case-crossover study included 98 patients with psoriasis. Exposure to drugs was assessed during a hazard period (3 months before hospitalization) and compared to a control period in the patient's past. Data on drug sales were extracted by data mining techniques. Multivariate analyses were performed by logistic regression and conditional logistic regression. In the case-control study, psoriasis was associated with benzodiazepines (OR 6.9), organic nitrates (OR 5.0), angiotensin-converting enzyme (ACE) inhibitors (OR 4.0) and non-steriodal anti-inflammatory drugs (NSAIDs) (OR 3.7). In the case-crossover study, psoriasis was associated with ACE inhibitors (OR 9.9), beta-blockers (OR 9.9), dipyrone (OR 4.9) and NSAIDs (OR 2.1). Extensive psoriasis may be associated with intake of ACE inhibitors, NSAIDs or beta-blockers.
引用
收藏
页码:299 / 303
页数:5
相关论文
共 25 条
[12]  
KATAYAMA H, 1981, Journal of Dermatology (Tokyo), V8, P323
[13]  
KATZ R, 1987, J AM ACAD DERMATOL, V17, P509, DOI 10.1016/S0190-9622(87)80368-7
[14]  
KOESTER H, 1974, DERMATOL MONATSSCHR, V160, P650
[15]   PSORIASIS INDUCED BY TOPICALLY APPLIED INDOMETHACIN [J].
LAZAROVA, AZ ;
TSANKOV, NK ;
ZLATKOV, NB .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1989, 14 (03) :260-261
[16]   Should we use a case-crossover design? [J].
Maclure, M ;
Mittleman, MA .
ANNUAL REVIEW OF PUBLIC HEALTH, 2000, 21 :193-221
[17]   THE CASE-CROSSOVER DESIGN - A METHOD FOR STUDYING TRANSIENT EFFECTS ON THE RISK OF ACUTE EVENTS [J].
MACLURE, M .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1991, 133 (02) :144-153
[18]  
Marshall R J, 2000, J Epidemiol Biostat, V5, P367
[19]   ANALYSIS OF CASE-CROSSOVER DESIGNS [J].
MARSHALL, RJ ;
JACKSON, RT .
STATISTICS IN MEDICINE, 1993, 12 (24) :2333-2341
[20]   EXACERBATION OF PSORIASIS BY INDOMETHACIN [J].
POWLES, AV ;
GRIFFITHS, CEM ;
SEIFERT, MH ;
FRY, L .
BRITISH JOURNAL OF DERMATOLOGY, 1987, 117 (06) :799-800